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Background:  A variety  of  -blockers  are  used  to control  heart  rate  (HR)  in atrial  ﬁbrillation  (AF);  how-
ever,  there  have  been  few  quantitative  assessments  of HR  and  blood  pressure  reductions  with  -blocker
monotherapy.
Methods  and results:  Seventy-eight  patients  with chronic  (persistent  or permanent)  AF  were  administered
bisoprolol  (2.5 mg/day)  for 2 weeks.  Subsequently,  48  patients  judged  to  require  a  dose  increase  were
either  continued  on  2.5 mg/day  (24 patients)  or administered  a higher  dose  (5 mg/day;  24 patients)  in  a
double-blind  fashion  for two further  weeks.  Change  in  mean  HR as  determined  by  Holter  electrocardio-
gram  was  the  primary  endpoint.  After  2 weeks  of bisoprolol  2.5  mg/day,  mean  HR  was  signiﬁcantly  lower
than  that before  treatment  (12.2  ± 9.1 beats/min,  p <  0.001).  Mean  HRs  in  the 5-mg  and  2.5-mg  continu-
ation  groups  were  also  signiﬁcantly  decreased  compared  with  those  before  treatment  (17.3  ±  12.9  and
11.4 ±  7.4  beats/min,  respectively,  both  p < 0.001),  with  a signiﬁcant  between-group  difference  (p  =  0.033).
The  HR  reduction  was  greater  during  the  day than at night.  Although  a greater  reduction  in  systolic  blood
pressure  was seen  in the  5-mg  group  than  in  the  2.5-mg  continuation  group,  the difference  between
groups  was not  signiﬁcant.  There  were  no serious  adverse  events.
Conclusions:  This  is the ﬁrst quantitative  analysis  of  -blocker  monotherapy  in  AF  patients.  Bisopro-
lol  exhibits  a dose-responsive  HR  reduction  when  administered  at sequential  doses  of  2.5  mg/day  and
5  mg/day.
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Several large clinical studies in Japan and in other countries [e.g.
he Atrial Fibrillation Follow-up Investigation of Rhythm Manage-
ent (AFFIRM) study [1] and the Japanese Rhythm Management
rial for Atrial Fibrillation (J-RHYTHM) [2]] have conﬁrmed the
sefulness of rate-control as being comparable to that of rhythm-
ontrol for treating atrial ﬁbrillation (AF). Treatment guidelines
n the USA, Europe, and Japan recommend -blockers as a rate-
ontrol treatment option for AF [3–5]. However, because all of the
-blockers used to treat AF have been considered as belonging
o a single class, there is little evidence regarding their effective-
ess, such as heart rate and blood pressure reduction, or adverse
eactions for individual -blockers. A typical example is bisopro-
ol, which is already used off-label as a primary -blocker [6–10].
owever, no prospective studies have attempted to quantitatively
 MAIN-AF: Multi-center trial for the Assessment of heart rate control by
isoprolol IN patients with chronic Atrial Fibrillation.
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assess the heart rate and blood pressure reductions with bisoprolol.
Consequently, the doses of bisoprolol used in clinical practice are
selected by trial and error. Therefore, we conducted a clinical study
to determine the optimal dose of bisoprolol in Japanese patients
with AF.
Methods
Patients
Outpatients aged 20–79 years with a diagnosis of chronic
(persistent or permanent) AF and whose resting heart rate was
≥80 beats/min on 12-lead electrocardiogram (ECG) and systolic
blood pressure ≥110 mmHg were eligible for this study. All patients
voluntarily provided written informed consent to participate in this
study before entering the study.
Patients meeting any of the following criteria were excluded:
patients with heart failure, cardiomyopathy, cardiogenic shock, or
myocarditis; patients with cardiac dysfunction (e.g. left ventricular
ejection fraction <50%); patients with serious arrhythmia, includ-
ing atrioventricular block (second or third degree), sinoatrial block,
and sick sinus syndrome; patients with severe aortic or mitral
vier Ltd. All rights reserved.
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alve stenosis/regurgitation; patients with an implanted device,
uch as a pacemaker, implantable cardioverter-deﬁbrillator (ICD),
r a device for cardiac resynchronization therapy whose heart rate
as being controlled; patients with myocardial infarction, who
ad undergone cardiovascular surgery (e.g. percutaneous coronary
ntervention or surgical ablation), or who had experienced atypi-
al or unstable angina in the previous 6 months; and patients who
ad undergone electrical deﬁbrillation or catheter ablation in the
revious 3 months. Patients were also excluded for the following
easons: patients contraindicated for -blockers; patients with a
istory of stroke or other cerebrovascular disorder; patients con-
raindicated for anticoagulant therapy.
-Blockers, diltiazem, verapamil, antiarrhythmics, and car-
iotonic drugs (including digitalis) were not permitted to be
dministered concomitantly with bisoprolol starting from 1 week
rior to the start of treatment period 1 (6 months prior in the case
f amiodarone).
tudy design
The study was conducted at 22 sites in Japan between 2011
nd 2012. Approval was obtained from the institutional review
oards at each participating institution before starting the study.
he study was conducted with reference to the ethical princi-
les of the Declaration of Helsinki and Good Clinical Practice
GCP).
The study was a prospective investigation consisting of four
eriods, including a 1- to 4-week screening period, a 2-week
on-randomized open-label treatment period (treatment period
), a 2-week randomized, double-blind treatment period (treat-
ent period 2), and a 2-week follow-up period (Fig. 1). After
onﬁrming study eligibility, enrolled patients started treatment
ith 2.5 mg  bisoprolol once daily in treatment period 1. At the end
f treatment period 1, patients fulﬁlling the dose increase crite-
ia (listed below) were randomized to either continue 2.5 mg/day
isoprolol or a higher dose of bisoprolol (5.0 mg/day) for a fur-
her 2 weeks (treatment period 2). The patients who  did not
ove on to treatment period 2 and the patients who  entered
he follow-up period could then receive other treatments as
ppropriate.
ig. 1. Study design. After a 1- to 4-week observation period, eligible patients started the
n  an open-label fashion. After completing efﬁcacy measures at the end of Week 2, pati
.5  mg/day bisoprolol or to a higher dose (5.0 mg/day) for 2 weeks (treatment period 2) i
-week  follow-up period. AF, atrial ﬁbrillation; ECG, electrocardiogram.Cardiology 62 (2013) 50–57 51
We used a dynamic randomization method to allocate the
patients based on whether the patient was pretreated with a
-blocker and heart rate before starting study treatment.
Dose increase criteria
Patients were eligible for a dose increase at the end of treatment
period 1 if they met  one of the following efﬁcacy and safety crite-
ria: (1) resting heart rate of ≥80 beats/min on 12-lead ECG and/or
subjective symptoms associated with AF (e.g. palpitations, short-
ness of breath, and chest discomfort) that did not resolve (efﬁcacy
criteria); (2) systolic blood pressure ≥110 mmHg  and resting heart
rate ≥70 beats/min on 12-lead ECG (safety criteria).
Data collection
The patients underwent the speciﬁed examinations and obser-
vations at Week 0 (start of treatment period 1), Week 2 (start
of treatment period 2), and Week 4 (end of treatment period 2).
Patients who did not fulﬁll the criteria for the dose increase under-
went measurements at Weeks 0 and 2.
For Holter ECG (Cardy 303 pico; Suzuken, Nagoya, Japan), the
monitor was  attached to the patient on the day before the exam-
ination, and ECG was measured for 24 h during routine daily
life. Efﬁcacy endpoints were the mean heart rate on Holter ECG,
resting heart rate on 12-lead ECG, subjective symptoms (pal-
pitations, shortness of breath, and chest discomfort) evaluated
during patient interviews, and the patient global impression (very
comfortable, comfortable, no change, uncomfortable, very uncom-
fortable). Blood pressure, clinical laboratory tests, and adverse
events were evaluated as the safety endpoints.
Statistical analysis
The efﬁcacy analysis was  performed for the full analysis set
(FAS), which was  deﬁned as all patients that remained after exclud-
ing those without chronic AF, those who did not receive the study
drug, and those for whom there were no efﬁcacy data. Robustness
was examined in a secondary analysis using the per-protocol set
(PPS), after excluding patients from the FAS who did not fulﬁll the
 2-week treatment period 1 in which they were treated with 2.5 mg/day bisoprolol
ents meeting the criteria for a dose increase were randomized to either continue
n a double-blind manner. At the end of treatment period 2, the patients entered a
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nclusion criteria, met  any of the exclusion criteria, or who had
iolated the provisions on prohibited concomitant drugs and drug
dministration.
A paired t-test was used to compare the change in mean heart
ate, as determined by Holter ECG, between the start and the end
f treatment period 1. A paired t-test was also used to compare the
hange in mean heart rate, as determined by Holter ECG, between
he start of treatment period 1 and the end of treatment period 2
n the 5-mg group if the reduction in heart rate at the end of treat-
ent period 1 was statistically signiﬁcant (ﬁxed-sequence testing
ethod). A paired t-test was performed in patients who  continued
n 2.5 mg/day in treatment period 2. We  used analysis of covariance
ANCOVA) to compare the change in mean heart rate determined
sing Holter ECG between the two groups. In this analysis, treat-
ent group and prior treatment with -blockers were included as
actors and heart rate before starting the study drug was  included
s a covariate.
In all analyses, values of p < 0.05 were considered statistically
igniﬁcant. Values are presented as mean ± standard deviation for
ontinuous variables, or as n (%) for categorical variables. SAS ver-
ion 9.2 was used for all analyses.
esultsatient disposition
Of the 106 patients who  provided informed consent, 78 started
reatment period 1 and received 2.5 mg/day bisoprolol. After
Fig. 2. Patient dCardiology 62 (2013) 50–57
2 weeks of treatment, 48 patients were deemed to require a dose
increase and were randomly allocated in a double-blind manner to
either continue 2.5 mg/day bisoprolol (n = 24) or to receive a dose
increase to 5 mg/day bisoprolol (n = 24) for 2 weeks in treatment
period 2 (Fig. 2).
Patient characteristics
The patient characteristics according to treatment group are
summarized in Table 1. Nonequivalence (p < 0.15) between the two
dose groups was not seen for any of the items.
Heart rate
Mean heart rate on Holter ECG: Weeks 0–2 and 0–4
Mean heart rate determined by Holter ECG was examined. The
mean ± SD heart rate was 94.6 ± 14.0 beats/min at the start of treat-
ment period 1 and 82.4 ± 12.4 beats/min at the end of treatment
period 1. The decrease in heart rate was 12.2 ± 9.1 beats/min, which
was statistically signiﬁcant (paired t-test, p < 0.001). Because the
reduction in heart rate in treatment period 1 was statistically signif-
icant, we examined the change in mean heart rate in the 5-mg group
throughout treatment periods 1 and 2 (ﬁxed-sequence test). The
mean heart rate in this group was  99.8 ± 16.8 beats/min at the start
of treatment period 1 and 82.5 ± 10.7 beats/min at the end of treat-
ment period 2. The decrease in heart rate was 17.3 ± 12.9 beats/min,
which was statistically signiﬁcant (paired t-test, p < 0.001).
isposition.
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Table  1
Patient characteristics.
Enrolled into treatment period 1 Enrolled into treatment period 2
Bisoprolol dose 2.5-mg group 2.5-mg continuation group 5-mg group p-Valued
N 75 24 24
Sex
Male  50 (66.7) 18 (75.0) 13 (54.2) 0.227a
Female 25 (33.3) 6 (25.0) 11 (45.8)
Age  (years) 67.1 ± 8.9 65.3 ± 10.1 65.8 ± 8.5 0.854b
Height (cm) 163.21 ± 10.40 165.80 ± 9.49 161.59 ± 11.51 0.174b
Weight (kg) 69.25 ± 17.06 72.85 ± 18.28 70.45 ± 18.96 0.657b
Diagnosis
Chronic AF 75 (100.0) 24 (100.0) 24 (100.0)
Duration of chronic AF (years) 3.42 (0.0–20.0) 2.50 (0.1–20.0) 3.00 (0.0–14.5) 0.853c
Use of a -blockere
No 58 (77.3) 19 (79.2) 19 (79.2) 1.000a
Yes 17 (22.7) 5 (20.8) 5 (20.8)
Concomitant diseasef
No 5 (6.7) 1 (4.2) 1 (4.2) 1.000a
Yes 70 (93.3) 23 (95.8) 23 (95.8)
Hypertension 51 (68.0) 18 (75.0) 15 (62.5)
Dyslipidemia 30 (40.0) 12 (50.0) 5 (20.8)
Mitral valve incompetence 11 (14.7) 4 (16.7) 3 (12.5)
Diabetes mellitus 9 (12.0) 3 (12.5) 3 (12.5)
Other 60 (80.0) 21 (87.5) 19 (79.2)
Mean  heart rate on Holter ECG (beats/min) 94.8 ± 14.0 97.9 ± 12.9 99.8 ± 16.8 0.653b
Mean heart rate on resting 12-lead ECG (beats/min) 94.3 ± 13.7 99.1 ± 15.5 98.4 ± 14.4 0.878b
Subjective symptom: palpitationsg
None 48 (64.0) 15 (62.5) 11 (45.8) 0.385a
Mild 25 (33.3) 9 (37.5) 12 (50.0)
Moderate 2 (2.7) 0 (0.0) 1 (4.2)
Subjective symptoms: shortness of breathg
None 53 (70.7) 18 (75.0) 14 (58.3) 0.212a
Mild 20 (26.7) 5 (20.8) 10 (41.7)
Moderate 2 (2.7) 1 (4.2) 0 (0.0)
Subjective symptom: chest discomfortg
None 59 (78.7) 20 (83.3) 15 (62.5) 0.193a
Mild 16 (21.3) 4 (16.7) 9 (37.5)
Moderate 0 (0.0) 0 (0.0) 0 (0.0)
Systolic blood pressure (mmHg) 132.0 ± 13.0 129.3 ± 13.5 130.1 ± 9.2 0.814b
Diastolic blood pressure (mmHg) 82.4 ± 10.0 82.0 ± 11.0 81.0 ± 9.9 0.752b
Brain natriuretic peptide concentration (pg/mL) 137.58 ± 84.71 144.16 ± 90.99 140.58 ± 93.10 0.894b
Values are mean ± standard deviation, median (range) or n (%).
a Fisher’s exact test.
b t-Test.
c Wilcoxon rank-sum test.
d Tests for 2.5-mg continuation group versus 5-mg group.
e Use of a -blocker on the day of study enrollment and within 6 months before study enrollment.
f MedDRA/J version 14.1.
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F, atrial ﬁbrillation; ECG, electrocardiogram.
n patients who continued treatment with 2.5 mg/day bisoprolol in
reatment period 2, the mean heart rate was 97.9 ± 12.9 beats/min
t the start of treatment period 1 and 86.5 ± 11.2 beats/min at
he end of treatment period 2. The decrease in heart rate was
1.4 ± 7.4 beats/min, which was statistically signiﬁcant (paired
-test, p < 0.001). The least square (LS) mean difference between
he treatment groups (5-mg group – 2.5-mg continuation group)
or the change in mean heart rate was −5.0 beats/min (95% con-
dence interval [CI]: −9.5 to −0.4 beats/min). ANCOVA conﬁrmed
hat the mean heart rate in the 5-mg group was signiﬁcantly lower
han in the 2.5-mg continuation group (p = 0.033, Fig. 3).
Among the 78 patients that entered treatment period 1,
auses of >3 s were recorded in ﬁve patients at the start of
reatment period 1 and in 11 patients at the end of treatment
eriod 1. No patient had pauses of >4 s at any time during the
tudy.ean heart rate on Holter ECG: Weeks 2–4
We next compared the change in mean heart rate from the
nd of treatment period 1 to the end of treatment period 2.The mean heart rate in the 5-mg group decreased signiﬁcantly
by 2.6 ± 6.0 beats/min from 85.1 ± 12.1 beats/min at the end of
treatment period 1 to 82.5 ± 10.7 beats/min at the end of treat-
ment period 2 (paired t-test, p = 0.045). The mean heart rate in
the 2.5-mg continuation group decreased by 0.8 ± 6.6 beats/min,
from 87.3 ± 13.3 beats/min at the end of treatment period 1 to
86.5 ± 11.2 beats/min at the end of treatment period 2. How-
ever, the decrease was not statistically signiﬁcant (paired t-test,
p = 0.565).
The LS mean difference between the treatment groups (5-mg
group – 2.5-mg continuation group) for the change in mean heart
rate during treatment period 2 was  −2.3 beats/min (95% CI: −5.6 to
−0.9 beats/min, p = 0.154). Therefore, the reduction in mean heart
rate was greater in the 5-mg group compared with the 2.5-mg
continuation group.
Three patients in the 2.5-mg continuation group and two
patients in the 5-mg group had pauses of >3 s at the end of treat-
ment period 1, while two patients in each group had pauses of >3 s
at the end of treatment period 2. No patient had pauses of >4 s at
any time during the study.
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Fig. 3. Changes in mean heart rate determined by 24-h Holter electrocardiogram at
the  end of each treatment period (a) and over time (b). Values are mean ± standard
deviation. *One patient whose data after Week 2 were not available was  excluded.
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of treatment period 1 for both dose groups. As shown in Fig. 6,
F
rChange from the start of treatment period 1 to the end of treatment period 1.
Change in mean heart rate from the start of treatment period 1 to the end of
reatment period 2.
esting heart rate on 12-lead ECG
In the 5-mg group, the resting heart rate determined by 12-
ead ECG was 98.4 ± 14.4 beats/min at the start of treatment period
, 85.4 ± 12.5 beats/min at the end of treatment period 1, and
1.0 ± 15.8 at the end of treatment period 2, corresponding to a
ig. 4. Change in mean heart rate from the start of treatment period 1 to the end of treatm
ate  at the start of treatment period 1. Values are mean ± standard deviation.Cardiology 62 (2013) 50–57
decrease of 17.4 ± 14.3 beats/min from the start of treatment period
1 to the end of treatment period 2. In the 2.5-mg continuation
group, resting heart rate was  99.1 ± 15.5 beats/min at the start of
treatment period 1, 87.4 ± 13.4 beats/min at the end of treatment
period 1, and 84.8 ± 14.6 beats/min at the end of treatment period
2, corresponding to a decrease of 14.3 ± 7.2 beats/min from the start
of treatment period 1 to the end of treatment period 2. The changes
in resting heart rate were similar to the changes in mean heart rate
determined by Holter ECG.
Examination of patient subgroups
The changes in mean heart rate between the start of treat-
ment period 1 to the end of treatment period 2 were compared
among patients stratiﬁed by mean heart rate determined by Holter
ECG or resting heart rate on 12-lead ECG of ≥100 beats/min or
<100 beats/min at the start of treatment period 1. As shown in Fig. 4,
the reduction in mean heart rate was  greater in the patients whose
mean heart rate or resting heart rate at the start of treatment was
≥100 beats/min than in patients with mean or resting heart rate of
<100 beats/min. The magnitude of the reduction was  also greater
in the 5-mg group than in the 2.5-mg continuation group.
Blood pressure
Blood pressure decreased relatively mildly in both groups
(Fig. 5). The decrease in systolic blood pressure was  greater in the
5-mg group than in the 2.5-mg continuation group, although the
difference between the groups was not statistically signiﬁcant (two
sample t-test, p = 0.119).
Diurnal variation in heart rate
In both groups, the heart rate determined by Holter ECG was
lower at all times at the end of treatment period 2 than at the startthere were greater reductions in heart rate in the 5-mg group than
in the 2.5-mg continuation group. The reductions in heart rate were
greater during the day than at night.
ent period 2 determined by 24-h Holter electrocardioram (ECG) according to heart
T. Yamashita, H. Inoue / Journal of Cardiology 62 (2013) 50–57 55
Fig. 5. Changes in mean blood pressure over time. Values are mean ± standard devi-
ation. SBP, systolic blood pressure; DBP, diastolic blood pressure.
Fig. 6. Changes in diurnal mean heart rate determined by 24-h Holter electrocar-
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was comparable with both ECG methods for the overall cohort of
patients. Consequently, in the absence of symptoms, the reductioniogram. Values are means for data recorded at the start treatment period 1 and at
he end of treatment period 2 according to bisoprolol dose.
ubjective symptoms
Subjective symptoms, such as palpitations, shortness of breath,
nd chest discomfort, were examined. There was a trend toward an
mprovement in subjective symptoms, as the proportion of patients
ithout symptoms increased in both the 2.5-mg continuation and
he 5-mg groups.
atient impressions
Patient impressions were determined at the end of treatment
eriod 2 relative to that at the end of treatment period 1. The most
ommon response was “no change” in 50.0% (12/24) of patients in
he 5-mg/day group and 70.8% (17/24) in the 2.5-mg/day continua-
ion group. The second-most common response was “comfortable,”
hich was reported by a greater proportion of patients in the 5-mg
roup (45.8%, 11/24) than in the 2.5-mg continuation group (29.2%,
/24, Fig. 7).
dverse events
No serious adverse events or adverse events that led to study
ithdrawal occurred. Furthermore, there were no events (e.g.
ypotension or bradycardia) of particular concern during treatment
ith -blockers.Fig. 7. Patient impressions at the end of treatment period 2.
Discussion
The main ﬁndings of the present study were as follows: (1) biso-
prolol decreased the mean heart rate in a dose-dependent manner,
with a greater reduction in patients treated with 5.0 mg/day biso-
prolol than in patients treated with 2.5 mg/day bisoprolol (17.3 vs
11.4 beats/min), without major adverse events; (2) the reduction
in heart rate was  greater in patients with rapid ventricular activity
at baseline (i.e. ≥100 beats/min) than in those with slower ventri-
cular activity (i.e. <100 beats/min); and (3) the reduction in heart
rate was  greater during the day than at night. To the best of our
knowledge, this is the ﬁrst study to quantify the effects of a speciﬁc
-blocker, bisoprolol, on AF. Our results provide insights into the
beneﬁts of performing rate-control in an effective and safe manner.
Large studies conducted in other countries, such as the AFFIRM
study [1], the Rate Control versus Electrical Cardioversion (RACE)
for persistent atrial ﬁbrillation study [11], and the Strategies of
Treatment of Atrial Fibrillation (STAF) study [12], as well as the
large-scale J-RHYTHM study in Japan [2,5], have suggested that
rate-control provides clinically relevant improvements in persis-
tent AF. Those studies also indicated that the improvements in
the patient’s prognosis and tolerability with rate-control tended
to be equivalent or superior to those with rhythm-control based on
anti-arrhythmic drugs. These ﬁndings indicate that rate-control is
becoming a more important treatment strategy for chronic AF than
previously [13]. In actual clinical settings, however, there is a lack
of speciﬁc information that can be referred to when considering the
use of rate-control.
Only recently have studies (e.g. RACE II [14]) sought to deter-
mine the target heart rates, and there is little speciﬁc information
on the reductions in heart rate achieved by a single drug.
The present study showed a consistent beneﬁcial effect of
treatment with 2.5 mg/day bisoprolol for 2 weeks, as we found a
signiﬁcant reduction in mean heart rate determined by Holter ECG
of approximately10 beats/min. Moreover, among patients whose
heart rate did not decrease to <80 beats/min or who remained
symptomatic, increasing the dose to 5 mg/day was more effective
in terms of the reduction in heart rate compared with continu-
ing 2.5 mg/day for 2 more weeks. We  also found that the higher
dose was  well tolerated, with relatively few adverse drug reac-
tions. Our results in patients with chronic AF are consistent with
those of an earlier retrospective clinical study in Japan [7]. That
study also found signiﬁcant reductions in heart rate of 9.3 beats/min
with 2.5 mg/day bisoprolol and 15.8 beats/min with 5 mg/day biso-
prolol in patients with AF, including paroxysmal AF (intergroup
difference, two-sample t-test, p = 0.004) [7].
We also found in this study that bisoprolol reduced resting heart
rate determined by 12-lead ECG. Because 12-lead ECG is easier to
perform than Holter ECG, this ﬁnding will be of particular relevance
to routine clinical practice [15]. Notably, the reduction in heart ratein heart rate, as determined by 12-lead ECG, is likely to be an indica-
tor for implementing rate-control. However, this may not apply to
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atients with symptoms, in which case treatment decisions should
e made for individual patients.
An examination of subgroups of patients stratiﬁed by heart
ate of <100 or ≥100 beats/min at the start of treatment revealed
 greater reduction in mean heart rate in patients with higher
retreatment heart rates. Moreover, an examination of the diur-
al variation in mean heart rate showed a greater reduction in
eart rate during the day, with no facilitation of bradycardia at
ight. These ﬁndings are likely to be related to the pharmacologic
ffects of bisoprolol. For example, sympathetic tone is thought to
e increased in patients with a high mean heart rate and during the
ay. Accordingly, it seems reasonable that the sympathetic block-
ng effect of bisoprolol is greatest in these circumstances. In this
espect, bisoprolol differs greatly from digitalis, which enhances
octurnal bradycardia, and the effects of bisoprolol under these
onditions may  also differ from those of calcium antagonists.
While heart rate showed a signiﬁcant, dose-responsive
ecrease, blood pressure decreased much more mildly. One expla-
ation is that, although many of the patients had hypertension
s a concomitant disease, most were taking an antihypertensive
rug, such as an angiotensin receptor blocker or diuretic, during
he study. Therefore, their blood pressure was closer to or within
he normal range before starting treatment with bisoprolol.
Treatment with rate-control is thought to maintain the quality
f life (QOL) of patients with chronic AF, for whom conversion to
inus rhythm cannot be expected [5]. Although many of the patients
n this study lacked subjective symptoms before starting treatment,
hose with subjective symptoms reported a trend toward improve-
ents in their symptoms during bisoprolol treatment. Although
valuating patients’ impression in the open-label setting is mean-
ngless, in the blind setting it is more meaningful. The proportion of
atients whose impression of their condition improved was  higher
n the 5-mg group than in the 2.5-mg continuation group in the
ouble-blind phase (treatment period 2). Although these ﬁndings
uggest that bisoprolol is useful from a QOL perspective, a larger
tudy of patients, particularly symptomatic patients, may  be nec-
ssary to conﬁrm these ﬁndings.
As society ages, not only is the incidence of concurrent under-
ying heart disease increasing in patients with AF, but so is the
ikelihood of a latent decrease in cardiac function. Currently, there
re no deﬁnitive conclusions on the role of rate-control in such
atients. Because very few of the patients in the present study
ad obvious concomitant heart disease, we could not address this
ssue. However, bisoprolol has been reported to have beneﬁcial
ffects in individuals with heart failure, making it a promising
reatment option. The results of the present study suggest that
eart rate can be safely controlled in patients with normal car-
iac function by increasing the bisoprolol dose from 2.5 mg/day
o 5 mg/day.
Several limitations of this study should be discussed. First, in
he initial treatment period, patients were treated with bisoprolol
n an open-label manner, without a placebo group, because of ethi-
al issues. Second, QOL could not be adequately evaluated because
f the small number of patients enrolled. Third, the duration of
reatment was relatively short, and this may  be shorter than the
uration of treatment in routine clinical practice.
In conclusion, the results of this prospective clinical study show
hat bisoprolol dose-dependently reduces heart rate measured
sing a Holter ECG and resting 12-lead ECG in Japanese patients
ith chronic AF, with a good safety proﬁle. These results provide
vidence for the efﬁcacy of a rate-control strategy for chronic AF, in
hich the patient starts on a bisoprolol dose of 2.5 mg/day, which
an then be increased to 5 mg/day if the heart rate remains high
r in the presence of symptoms. This strategy provided clinically
eaningful heart rate reductions, which should be appropriate for
outine clinical practice.
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